- Home
- EBMT vs ALXO Comparison
EBMT vs ALXO Comparison
Compare EBMT & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EBMT | ALXO |
|---|---|---|
| Founded | 1922 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 175.7M | 205.9M |
| IPO Year | 2009 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EBMT | ALXO |
|---|---|---|
| Price | $21.28 | $1.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $25.00 | $4.60 |
| AVG Volume (30 Days) | 19.7K | ★ 930.4K |
| Earning Date | 10-27-2026 | 11-06-2026 |
| Dividend Yield | ★ 2.80% | N/A |
| EPS Growth | ★ 53.23 | 26.36 |
| EPS | ★ 0.98 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.89 | N/A |
| Revenue Next Year | $4.06 | N/A |
| P/E Ratio | $21.71 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.80 | $1.05 |
| 52 Week High | $24.66 | $2.66 |
Technical Indicators
Market Signals| Indicator | EBMT | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 32.00 | 29.67 |
| Support Level | $20.00 | $1.37 |
| Resistance Level | $22.74 | $1.56 |
| Average True Range (ATR) | 0.50 | 0.10 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 4.42 | 12.32 |
Price Performance
Historical ComparisonAbout EBMT Eagle Bancorp Montana Inc.
Eagle Bancorp Montana Inc operates as a bank holding company. It provides loan and deposit services. The company focuses on residential loans, commercial real estate loans, commercial loans, consumer loans, and home equity loan products. The bank also offers deposit accounts which include checking, savings, money market, individual retirement accounts, and certificates of deposit accounts. It is a diversified lender with a focus on residential mortgage loans, commercial real estate mortgage loans, commercial business loans, agricultural loans, and second mortgage/home equity loan products.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.